Shareholder Rights Investigation: The Ademi Firm is investigating VYNE's transaction with Yarrow Bioscience for potential breaches of fiduciary duty, which could undermine shareholder trust in corporate governance.
Shareholder Structure Shift: Post-transaction, VYNE shareholders are expected to own approximately 3% of the combined entity, while Yarrow shareholders will hold about 97%, significantly diminishing VYNE shareholders' control.
Competitive Transaction Restrictions: The transaction agreement imposes significant penalties on VYNE for accepting competing bids, potentially harming shareholder interests and limiting the company's strategic options in the future.
Board Accountability Review: The Ademi Firm is examining the conduct of VYNE's board to determine if they are fulfilling their fiduciary duties to all shareholders, which could impact the company's governance structure and future decision-making.
VYNE
$0.5849+Infinity%1D
Analyst Views on VYNE
Wall Street analysts forecast VYNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYNE is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast VYNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYNE is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.600
Low
2.00
Averages
2.00
High
2.00
Current: 0.600
Low
2.00
Averages
2.00
High
2.00
H.C. Wainwright
Joseph Pantginis
Buy
to
Neutral
downgrade
2025-07-30
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
2025-07-30
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics to Neutral from Buy.
H.C. Wainwright
H.C. Wainwright
Buy
to
Neutral
downgrade
$4.50
2025-07-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$4.50
2025-07-30
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright downgraded VYNE Therapeutics to Neutral from Buy and removed the firm's prior $4.50 price target after the company's Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The Phase 2b result is "a surprise to us" that "puts the company in a precarious position," the analyst tells investors. While stating that the company ends this trial in "a relatively stable financial position," the firm says the current risk profile "pushes us to the sidelines," pending visibility on the path forward for repibresib, additional VYN202 data and/or the acquisition of new assets to pursue.
BTIG
Julien Harrison
Buy -> Neutral
downgrade
2025-07-30
Reason
BTIG
Julien Harrison
Price Target
2025-07-30
downgrade
Buy -> Neutral
Reason
BTIG analyst Julien Harrison downgraded VYNE Therapeutics to Neutral from Buy with no price target after the company's Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The full data set will be further analyzed to inform results and strategic next steps, while the management intends to seek a development and commercialization partner for repibresib and plans to provide an update on repibresib and VYN202, which is currently on partial clinical hold by the FDA, plans in the coming weeks, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Neutral
downgrade
2025-04-25
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-04-25
downgrade
Neutral
Reason
H.C. Wainwright lowered the firm's price target on VYNE Therapeutics to $4.50 from $5.75 and keeps a Neutral rating on the shares after the FDA placed a clinical hold on the company;s Phase 1b study evaluating VYN202 in moderate-to-severe plaque psoriasis. The firm finds it important that there have been no serious adverse events observed in subjects that have been enrolled in the Phase 1b study to date. It should also be underscored that this clinical hold only applies to the VYV202 program, the analyst tells investors in a research note. VYNE's ongoing Phase 2b trial assessing repibresib gel in nonsegmental vitiligo continues without interruption, contends H.C. Wainwright.
About VYNE
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
